Published in Clin Cancer Res on November 01, 2008
Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal (2009) 2.33
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol (2012) 1.30
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol (2013) 1.23
Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer (2011) 1.19
Targeting the metabolic microenvironment of tumors. Adv Pharmacol (2012) 1.11
Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol (2011) 0.94
Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. Philos Trans R Soc Lond B Biol Sci (2014) 0.92
Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol (2016) 0.84
Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics. Bioorg Med Chem Lett (2009) 0.83
Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling. Front Oncol (2013) 0.75
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res (2008) 3.98
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science (2010) 2.99
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol (2004) 2.09
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck (2011) 1.97
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer (2008) 1.92
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res (2005) 1.73
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69
Bedside technique to detect misplaced subclavian vein catheter in internal jugular vein. Ann Card Anaesth (2010) 1.62
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res (2006) 1.60
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res (2012) 1.60
Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res (2012) 1.50
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk (2012) 1.48
Identical glycine substitution mutations in type VII collagen may underlie both dominant and recessive forms of dystrophic epidermolysis bullosa. Acta Derm Venereol (2011) 1.46
Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol (2012) 1.46
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs (2009) 1.41
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Intraoperative detection of a stuck bioprosthetic mitral valve leaflet causing severe mitral regurgitation. J Cardiothorac Vasc Anesth (2011) 1.38
Management of lip hemangiomas: Minimizing peri-oral scars. J Plast Reconstr Aesthet Surg (2011) 1.37
A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res (2014) 1.35
Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck (2010) 1.34
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res (2010) 1.30
The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol (2007) 1.29
Retracted Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol Pharmacol (2007) 1.28
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res (2012) 1.27
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest (2011) 1.27
Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol (2010) 1.26
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res (2010) 1.22
Human papillomavirus infections in laryngeal cancer. Head Neck (2011) 1.22
Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res (2008) 1.20
Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res (2008) 1.18
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2007) 1.15
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol (2010) 1.15
Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. PLoS One (2012) 1.14
Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res (2008) 1.14
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 1.13
Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck (2011) 1.13
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res (2007) 1.12
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol (2003) 1.12
The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs (2004) 1.12
Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol (2012) 1.10
Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res (2002) 1.10
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett (2012) 1.06
The Pim kinases: new targets for drug development. Curr Drug Targets (2011) 1.06
Differential tissue and subcellular expressionof ERM proteins in normal and malignant tissues: cytoplasmic ezrin expression has prognostic signficance for head and neck squamous cell carcinoma. Head Neck (2006) 1.05
Proposal for a rational classification of neck dissections. Head Neck (2010) 1.04
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther (2002) 1.04
Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res (2008) 1.02
Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos (2012) 1.02
Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck (2014) 1.02
Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway. J Pharmacol Exp Ther (2013) 1.02
Improved outcomes for lap-banding using the Insuflow device compared with heated-only gas. JSLS (2009) 1.01
Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol (2009) 1.01
In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol (2011) 1.01
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res (2007) 1.01
Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res (2006) 1.01
Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2012) 1.00
Diagnosis and treatment of recurrent laryngeal cancer following initial nonsurgical therapy. Head Neck (2011) 0.99
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res (2007) 0.99
Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol (2008) 0.98
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res (2010) 0.98
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol Cancer Ther (2011) 0.98
Cochlin in the eye: functional implications. Prog Retin Eye Res (2007) 0.98
Reovirus: a targeted therapeutic--progress and potential. Mol Cancer Res (2012) 0.98
Combined P16 and human papillomavirus testing predicts head and neck cancer survival. Int J Cancer (2014) 0.98
An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res (2009) 0.97
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol (2004) 0.97
Orphan nuclear receptors as targets for drug development. Pharm Res (2010) 0.97
Acetylation of pregnane X receptor protein determines selective function independent of ligand activation. Biochem Biophys Res Commun (2011) 0.96
Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling. Br J Nutr (2013) 0.96
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemother Pharmacol (2011) 0.96
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother Pharmacol (2006) 0.95
Post-translational modification of pregnane x receptor. Pharmacol Res (2011) 0.95
Lung cancer in HIV Infection. Clin Lung Cancer (2011) 0.95
Complementary and alternative medicine among Singapore cancer patients. Ann Acad Med Singapore (2010) 0.94
Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol (2011) 0.94
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment. Head Neck Pathol (2013) 0.93
Leiomyomas beyond the uterus; benign metastasizing leiomyomatosis with paraaortic metastasizing endometriosis and intravenous leiomyomatosis: a case series and review of the literature. Arch Gynecol Obstet (2014) 0.93
Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet (2013) 0.93
Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemother Res Pract (2012) 0.92
Radiofrequency ablation of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (2011) 0.92
Future of the TNM classification and staging system in head and neck cancer. Head Neck (2010) 0.92
Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol (2013) 0.92
Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol (2013) 0.91
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol (2014) 0.90
Metastatic apocrine carcinoma of the scalp: prolonged response to systemic chemotherapy. J Clin Oncol (2010) 0.90
Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily. Curr Drug Metab (2013) 0.90
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol (2013) 0.90
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res (2011) 0.89
Contemporary management of cancer of the oral cavity. Eur Arch Otorhinolaryngol (2010) 0.89